ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1356	National Cancer Institute	Html	en	Carcinoma of Unknown Primary Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of metastatic cancer that has spread from an unidentified primary tumor.	general cancer information 0.411851 treatment 0.656267 cancer treatment 0.493001 breast cancer cells 0.486603 primary cancer 0.600191 new cancer treatments 0.408458 Peritoneal Cancer Treatment 0.426103 cancer cells 0.712358 tissue 0.443805 malignant tumor cells 0.423112 body 0.560831 type 0.447878 Cancer Information Service 0.414189 Squamous Neck Cancer 0.400297 PDQ cancer information 0.512966 clinical trial search 0.39505 treatment clinical trials 0.437756 certain changes 0.407705 National Cancer Institute 0.54586 clinical trials 0.823063 normal cells 0.410928 cancer information summary 0.471688 clinical trial 0.588388 new treatment 0.44726	breast cancer prevention 0.400005 primary cancer site 0.517081 cancer tissue 0.403216 patients 0.429603 Cancer Care page 0.397493 PDQ summary 0.435669 treatment clinical trial 0.401935 PDQ Adult Treatment 0.398071 NCI PDQ cancer 0.432436 cancer research process 0.400715 cancer clinical trials 0.44656 tests 0.388491 lymph nodes 0.409196 Unknown Primary Treatment 0.395812 carcinoma 0.39749 primary cancer depend 0.439856 lymph node 0.431668 radiation therapy 0.485838 Treatment Editorial Board 0.413559 cancer information summaries 0.411898 comprehensive cancer information 0.411754 cancer 0.945761 standard treatment 0.426236	CLICK HERE
1849	National Cancer Institute	Html	es	Tratamiento del cáncer de próstata (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de próstata.	Compton CC 0.32822 preoperative nomogram 0.351745 outcome after 0.326979 progression after psa 0.331315 Albertsen PC 0.319652 prostate specific 0.36016 clinically localized 0.351298 Kabalin JN 0.319448 American Cancer Society 0.354812 Radical prostatectomy versus 0.362604 Eastham JA 0.338512 versus watchful waiting 0.321163 following radical prostatectomy 0.340792 PSA anormal 0.32618 7th ed 0.328183 Radiat Oncol Biol 0.401027 Estados Unidos 0.34545 Natl Cancer Inst 0.962766 cancer staging 0.41957 men with 0.323828 Stamey TA 0.333393 Radical prostatectomy treated 0.32026 Union Against Cancer 0.327902 versus gleason 0.324714 prostate biopsy 0.325976	with psa testing 0.327026 ecografía transrectal 0.331137 prostate with radiotherapy 0.319235 Cancer Facts 0.330577 gammagrafía ósea 0.32132 radical prostatectomy 0.783813 after radical prostatectomy 0.482799 Cancer Staging Manual 0.40851 recurrence after 0.340439 New York 0.323092 Clin Oncol 0.387513 predict pathological stage 0.323561 Oncol Biol Phys 0.404255 Oncology Consensus Panel 0.323099 Kattan MW 0.336259 systematic review 0.320343 with clinically localized 0.323887 Byrd DR 0.326227 American Joint Committee 0.318729 Partin AW 0.341859 transrectal ultrasound guided 0.325554 AJCC Cancer Staging 0.413497 Edge SB 0.328269 PSA following 0.325762	CLICK HERE
1939	National Cancer Institute	Html	es	Adaptación al cáncer: ansiedad y sufrimiento (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las difíciles respuestas emocionales que se presentan en muchos de los pacientes con cáncer. Este sumario se enfoca en asuntos de la adaptación normal, alteración psicosocial y trastornos de adaptación.	La espiritualidad 0.829227 siguientes aspectos 0.951689 intensa ansiedad 0.886965 siguientes tipos 0.835996 largo plazo 0.911949 ¿Qué efectos 0.840354 siguientes períodos 0.85698 siguientes síntomas 0.824791 siguientes riesgos 0.776419 Visuals Online 0.784027 Physician Data 0.774429 siguientes problemas 0.817253	siguientes factores 0.894404 Mucha transpiración 0.807275 resultados correctos 0.846693 libre uso 0.789 siguientes situaciones 0.941031 Data Query 0.774207 siguientes características 0.904197 Cancer Institute 0.786402 página manejo 0.784108 suficiente dinero 0.80221 siguientes sumarios 0.945414 usa compulsiones 0.805006	CLICK HERE
2013	National Cancer Institute	Html	es	Aspectos generales de los exámenes de detección del cáncer (PDQ®)–Versión para pacientes	Información sobre la medición de la eficacia de los exámenes de detección del cáncer y la evaluación de la solidez de las pruebas obtenidas en estudios de investigación de detección del cáncer.	suficiente información 0.640426 riesgos.Algunos exámenes 0.948845 posibles factores 0.658466 End Results 0.782283 siguientes aspectos 0.657281 cabo ensayos 0.656668 ¿Los exámenes 0.83489 siguientes tipos 0.726625 efecto secundario adverso 0.681584 cuánto tiempo 0.658052 grupo pacientes 0.645515 información ayuda 0.635388 National Cancer Institute 0.643177	siguientes riesgos 0.629124 Instituto Nacional 0.984309 antecedentes familiares 0.663533 suficientes pruebas 0.65243 Physician Data Query 0.768953 Estados Unidos 0.927922 menor tiempo 0.639093 única razón 0.651582 posibles beneficios 0.675509 determinada enfermedad 0.640319 cuáles pruebas 0.82218 términos riesgo 0.746808 PDQ Aspectos 0.65214	CLICK HERE
2068	National Cancer Institute	Html	es	Marcadores de tumores	Hoja informativa que explica lo que son los marcadores de tumores y responde preguntas sobre su uso para el diagnóstico y tratamiento del cáncer.	Bast RC Jr 0.727949 cancer screening 0.603977 Gray RJ 0.462067 randomized european study 0.51305 Asociación Estadounidense 0.468124 estudio plco 0.461327 Bigbee W 0.467579 amplia gama 0.464843 afecciones benignas 0.671952 Herberman RB 0.469893 Prevention Research 0.463207 BC Decker Inc 0.509079 Clinical Laboratory Improvement 0.519898 Cancer Screening Randomized 0.544857 Controlled Trial 0.467216 riesgo intermedio 0.462476 Clinical Practice 0.47196 ecografía transvaginal 0.471751 Makower DF 0.466396 estudio tailorx 0.460805 ¿Cuáles marcadores 0.637902 21-gene expression assay 0.514014	Hugosson J 0.463892 Instituto Nacional 0.461324 screening trial specimens 0.541412 Oncología Clínica 0.463202 tumor markers 0.619108 Andriole G 0.463781 Mortality results from 0.526447 Quality Requirements 0.470424 Kufe DW 0.468535 Black A 0.461077 6th ed 0.467056 Oncotype DX® 0.469566 situaciones benignas 0.492829 PubMed Abstract 0.928354 tratamientos resultantes 0.466203 Buys SS 0.460749 Bioquímica Clínica 0.461341 Pollock RE 0.46616 New England Journal 0.930005 Roobol MJ 0.466517 Sparano JA 0.466154 hoja informativa estadificación 0.539118	CLICK HERE
3582	National Cancer Institute	Html	en	Frederick National Laboratory for Cancer Research	The FNLCR combines private sector business practices with government infrastructure to conduct research and development in cancer and AIDS.	Frederick National Lab 0.679634 Development Center—one 0.586036 Federally Funded Research 0.723777 FNLCR 0.617129 biomarker identification 0.53533 animal sciences 0.53568 national resource 0.541398 government agencies 0.530109 human clinical trials 0.61809 preclinical assay development 0.712354 oncology-focused computational science 0.628628 cancer research laboratories 0.757218 early development 0.553877 research reagents 0.571396 NCI 0.666268 genetically engineered mouse 0.603734 preclinical research 0.638044 nonprofit research organizations 0.690454 broad charter 0.538883 Leidos Biomedical Research 0.735212 United States 0.647036 Nanotechnology Characterization Laboratory 0.625355 RAS family 0.527528 clinical practice 0.533965	NCI investigators 0.632716 significant cancer research 0.722685 translational genomics 0.544933 cancer research 0.952491 private sector business 0.653242 new drug development 0.647375 government sponsors 0.545164 biomedical research community 0.670235 development needs 0.584975 cancer researchers 0.562687 clinical operations 0.542191 Frederick National Laboratory 0.684108 government infrastructure 0.535486 technical staff 0.530406 preclinical model development 0.704349 private sector resources 0.635668 FNLCR programs 0.564698 National lab staff 0.628876 biomedical computing 0.548325 new cancer therapies 0.637914 frozen tumor samples 0.605424 nanotechnology applications 0.53469 cancer research enterprise 0.705608 basic research 0.59861	CLICK HERE
3675	National Cancer Institute	Html	en	Data Submission Under the Genomic Data Sharing (GDS) Policy	Information for intramural, extramural, and non-NIH funded investigators looking to submit study data under the Genomic Data Sharing (GDS) Policy.	data instruments 0.389578 Different submission requirements 0.358856 Different data types 0.458311 data 0.914172 N/A Arrays 0.352863 Institutional Certification 0.390929 data use limitations 0.365334 phenotype data 0.455331 DNA sequence data 0.507348 clinical information 0.351464 N/A .BAM Arrays 0.717463 common data elements 0.45555 NCI intramural research 0.372571 RNAseq data 0.381683 submission process 0.341088 SNP array data 0.440533 Data reuse 0.406127 genomic data 0.788599 genomic program administrator 0.366093 controlled-access genomic data 0.507551 Raw data 0.388186 bisulfite sequencing data 0.488737 data sharing plan 0.431561 scientific review 0.378953	basis N/A .TXT 0.57172 GWAS data 0.384745 data standards 0.487591 published table 0.34424 human genomic data 0.471234 additional research questions 0.363874 data processing 0.449487 GDS policy-covered research 0.360223 human sample data 0.554048 GDS website 0.358009 DNA methylation data 0.435253 NIH data repositories 0.466908 minimizes potential errors 0.345345 data generation 0.367981 Developing Data Sharing 0.429887 exposure data 0.441991 well-documented data standards 0.480779 genomic data—such 0.394593 data submission 0.621641 data release 0.391289 NIH National Center 0.357378 genomic data submissions 0.597871 N/A .BAM NGS 0.52976	CLICK HERE
15480	National Cancer Institute	Html	en	Grantees or Grant Applicants Submitting Data	In order to be compliant with the Genomic Data Sharing (GDS) Policy, extramural investigators should use the following to guide their steps through the grant life-cycle process.	annual Progress Report 0.62504 data 0.849889 Institutional Certification 0.882661 similar manner 0.478201 accession number 0.48592 section 0.333306 PO/PD 0.491096 Assignment 0.33161 approved DSP 0.538409 extramural investigators 0.782153 1. Plan Project 0.689974 Basic Study Information 0.674507 grant funding 0.568662 confirmation 0.333875 steps 0.331094 ARA 0.342301 submission portal 0.610861 plans 0.336284 grant application 0.941037 receipt 0.33802 GDS policy 0.525866 Upload Data 0.545134 dbGaP staff 0.485771 data certification process 0.735794 program officer/program director 0.674634	grants process 0.480049 grant life-cycle process 0.816123 Basic Information form 0.63633 dbGaP Study Release 0.648367 DSPs 0.34954 initiation 0.332734 pre-award process 0.509608 submission process 0.502601 required fields 0.479311 expectations 0.381962 place 0.332574 3. 0.332387 cleaning 0.332176 data submission formats 0.780089 study submission information 0.687432 Resource Sharing Plan 0.663305 QA/QC Data Submission 0.730259 Information form 0.651102 Submit Just-in-Time Materials 0.722172 Data Generation Completed 0.715899 GPA 0.642745 quality assurance check 0.641113 Write Grant Application 0.78666 data upload 0.531576	CLICK HERE
16713	National Cancer Institute	Html	es	Iniciativa de Respuestas Excepcionales: Preguntas y respuestas	El Instituto Nacional del Cáncer (NCI) emprendió la Iniciativa de Respuestas Excepcionales a fin de entender la base molecular de los tumores en pacientes de cáncer que responden en forma excepcional al tratamiento, principalmente quimioterapia.	Exceptional Responders 0.786989 suficiente información 0.61563 Sequencing Identifies 0.586522 poderosa técnica 0.577603 tejido no puede usarse para otras 0.723672 siguientes criterios 0.611344 llamado data access request 0.624892 ARN mensajero 0.581431 Everolimus Sensitivity 0.593577 suficiente ácido 0.633822 Genome Sequencing 0.743091 suficiente tejido 0.888254 genes tsc1 0.601267 datos dbGAP 0.580415 estudio piloto 0.664379 tejido fijo en formol 0.691726 Exceptional Responders Data 0.636284	Exceptional Responders Initiative 0.702067 consentimiento apropiado para investigaciones 0.678722 fármacos similares. El estudio 0.741131 Instituto Nacional 0.57833 gen tsc1 0.738554 Trials Support Unit 0.638511 descubrimientos prometedores 0.585883 datos clínicos a medidata 0.649717 Revisión Central de Adultos 0.624848 extensa experiencia 0.580712 requiere varios pasos 0.583341 pacientes con respuestas 0.618767 centro biospecimen core 0.880872 tumores sólidos 0.758056 enfermedad y el 0.583796 aun pacientes 0.751408	CLICK HERE
17222	National Cancer Institute	Html	en	Tumor DNA Sequencing in Cancer Treatment	Tumor DNA sequencing (also called genetic profiling or genetic testing) is a test to identify DNA changes in a patient’s cancer. In some cases, this information can help determine a treatment plan.	unique DNA changes 0.327494 health care provider 0.21495 lung tumor 0.253938 tumor sequencing 0.343527 specific genetic alterations 0.302101 healthy cells 0.230873 Multigene panel tests 0.208409 health care team 0.2107 frequently used sequencing 0.320207 hereditary cancer syndromes 0.221971 health care providers 0.211937 whole-genome sequencing 0.314537 cancer types 0.228448 DNA changes 0.331071 patient care 0.205253 targeted sequencing tests 0.342426 broad tumor DNA 0.375946 heterogeneous tumor 0.233471 DNA sequencing tests 0.507176 precision medicine 0.222532 single cancer type 0.228039 lung cancer cells 0.3596 treatment 0.286045 precision medicine trials 0.205063	DNA alteration 0.251455 NCI-COG Pediatric MATCH 0.207207 inherited genetic alteration 0.228682 DNA sequence 0.253453 cancer cells 0.454035 unique genetic alterations 0.280668 sequencing tests cost 0.308627 EGFR mutation 0.209321 Broad DNA sequencing 0.411749 cancer-causing DNA changes 0.297683 way cells function 0.250384 tumor dna 0.91525 tumor dna sequencing 0.748819 DNA sequencer 0.254089 Clinical tumor DNA 0.406068 health care 0.275099 DNA sequencing test 0.405098 mRNA expression test 0.209986 breast cancer 0.203535 genetic alterations 0.703142 cancer 0.512553 standard treatment 0.204466 whole-exome sequencing 0.314247 quantitative mRNA test 0.208612	CLICK HERE